PANACEA BIOTEC LTD.

Panacea Biotec Ltd. has filed details of shares dematerialised during September 2026, as per SEBI regulations. The company reported a total of 6,11,09,526 shares dematerialised as of September 30, 2026. This includes 5,25,61,875 shares through NSDL and 85,47,651 shares through CDSL. The filing also includes a certificate from their RTA, Skyline Financial Services Pvt. Ltd., confirming these figures. This report is a routine regulatory disclosure.

Panacea Biotec Ltd has received two demand orders dated September 28, 2026, from the Office of the Assistant Commissioner of Income Tax, Delhi. These orders impose a penalty aggregating to approximately ₹4.32 Crore for alleged misreporting or under-reporting of income for Assessment Years 2022-23 and 2023-24. The company believes the demand is not maintainable and is taking necessary steps, including filing an appeal with the appellate authority. Panacea Biotec does not anticipate any significant financial, operational, or other impact on the company.

Panacea Biotec Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure will commence on October 01, 2026, and will remain in effect until 48 hours after the announcement of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. This measure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct to prevent insider trading. The date of the board meeting to approve these financial results will be communicated separately.

Panacea Biotec Ltd has received four Demand Orders from the Assistant Commissioner of Income Tax, Delhi, totaling approximately ₹9.82 Crore. These penalties are imposed under Section 156 of the Income Tax Act, 1961, for alleged misreporting or under-reporting of income for assessment years 2014-15 to 2016-17 and 2018-19. The company stated that it believes the demand is not maintainable and is taking necessary steps, including filing an appeal. Panacea Biotec does not anticipate any significant impact on its financial, operational, or other activities.

Panacea Biotec Ltd is issuing reminder letters to shareholders holding shares in physical mode, urging them to furnish PAN and KYC details for updation. This action is in compliance with SEBI circulars mandating the recording of PAN, address, mobile number, bank account details, and specimen signatures for physical shareholders. Failure to update these details by April 1, 2024, will result in dividends being paid only through electronic mode and may restrict service requests. Shareholders are encouraged to provide nomination details as well. Forms for updation are available on the company's and registrar's websites.

Panacea Biotec Ltd has announced the 42nd Annual General Meeting (AGM) will be held on September 29, 2026, at 11:30 AM IST via Video Conferencing. The company's Register of Members and Share Transfer Books will be closed from September 25, 2026, to September 29, 2026, inclusive, for the AGM. The meeting agenda includes adopting the Audited Standalone and Consolidated Financial Statements for FY26, re-appointing directors Mr. Ankesh Jain and Mr. Harshet Jain, and appointing Mr. Rajinder Singh Manku as an independent director.

Panacea Biotec Ltd has informed shareholders about the dispatch of a letter providing a web-link to access the Annual Report for FY 2025-26 and the Notice for the upcoming 42nd Annual General Meeting (AGM). The AGM will be held on September 29, 2026, via Video Conferencing. Shareholders whose email addresses are not registered will receive this information through the provided web-link. The company also detailed the e-voting period, which runs from September 26 to September 28, 2026, with a cut-off date of September 22, 2026. Instructions for updating email addresses and KYC details are also provided.

Panacea Biotec Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as per SEBI regulations. The company is voluntarily complying with BRSR provisions, even though it may not fall within the top 1000 listed entities by market capitalization. The report details corporate identity, business activities primarily in pharmaceuticals (100% turnover), markets served (including ~37 countries internationally), and workforce representation. Exports contributed approximately 65% of the total turnover for the reporting year. The company supplies vaccines to multilateral agencies like UNICEF and PAHO, alongside institutional and private market customers.

Panacea Biotec Ltd has announced its 42nd Annual General Meeting (AGM) scheduled for September 29, 2026, to be held via Video Conferencing. The company has also released its Annual Report for the financial year 2025-26. The AGM will include the adoption of audited standalone and consolidated financial statements for FY26, re-appointment of directors Mr. Ankesh Jain and Mr. Harshet Jain, and the appointment of Mr. Rajinder Singh Manku as an independent director. Shareholders will have the opportunity to participate in remote e-voting from September 26 to September 28, 2026, with a cut-off date of September 22, 2026, for eligibility.

Panacea Biotec Ltd has announced its 42nd Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 11:30 A.M. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM) in compliance with MCA and SEBI regulations. The company has also attached its Annual Report for the financial year 2025-26 and the Notice of AGM. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY2025-26, and the re-appointment of directors Mr. Ankesh Jain and Mr. Harshet Jain. Additionally, the appointment of Mr. Rajinder Singh Manku as an independent director will be considered as a special business. The company is providing remote e-voting facilities for members, with the cut-off date for voting being September 22, 2026, and the voting period commencing on September 26, 2026.